Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
PPAR α antagonist
DRUG CLASS:
PPAR α antagonist
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
TPST-1120 (4)
TPST-1120 (4)
›
Associations
(4)
News
Trials
Search handles
@ArndtVogel
@MarkYarchoan
Search handles
@ArndtVogel
@MarkYarchoan
Filter by
Latest
12ms
🔥Tempest announces early results for combination of TPST-1120 with Atezo/Bev in 1st line HCC ✅TPST-1120 -> PPARα agonist 🔎phs 1b/2, 70 pts 👉ORR 30% vs 17% (lower than expected in AB arm) 🧐Promsing, are we on the way to triplet Tx in HCC? @myESMO @EASLedu #livertwitter… https://t.co/0S6Uof68sN (@ArndtVogel)
12 months ago
Clinical
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • TPST-1120
12ms
Interesting data from Roche/Morpheus #HCC program: bev/atezo+/-TPST1120 TSPT1120 = "metabolic CPI" targeting PPARa At early timepoint: 🔼ORR (30% vs. 17.2%) 🔼patients on tx (47.5% vs 23.3%) bev/atezo/TPST1120 is a promising HCC triplet https://t.co/xxAc3RrL0n (@MarkYarchoan)
12 months ago
Clinical
|
PPARA (Peroxisome Proliferator Activated Receptor Alpha)
|
Tecentriq (atezolizumab) • TPST-1120
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login